Matthew Ros, the Executive Vice President, Chief Strategy and Business Officer of Epizyme, Inc. (the ?Company?) will be leaving the Company to pursue other business opportunities following the Company?s decision to eliminate this role at this time. Grant Bogle, the Company?s President and Chief Executive Officer and a director of the Company, will serve as the Company?s principal financial officer, effective November 1, 2021 while the Company continues its search for a full-time Chief Financial Officer. Mr. Bogle, 63, has served as the Company?s President and Chief Executive Officer since August 2021 and as a director of the Company since September 2019. Prior to joining the Company, Mr. Bogle attended Harvard University as Senior Fellow in the 2020 cohort of the Advanced Leadership Initiative. From July 2015 to June 2019, Mr. Bogle served as Senior Vice President and Chief Commercial Officer of Tesaro, Inc, a biopharmaceutical company (?Tesaro?) and left the organization after the purchase of Tesaro by GlaxoSmithKline plc.